Skip to main content

Independent regulatory consultancy and EU Authorised Representative for medical device and IVD manufacturers since 1995.

Search Now!
Contact Info
Location Ernst-Heckel-Straße 7, 66386 St. Ingbert, Germany
Contact Info
Location Ernst-Heckel-Straße 7, 66386 St. Ingbert, Germany

Strategic Regulatory Consulting

CE conformity under MDR 2017/745 and IVDR 2017/746. Technical documentation, clinical evaluation per MDCG 2020-13 and ISO 14971 risk management — strategic and hands-on.

Strategic regulatory consulting

Complete support for European pre- and post-market compliance

Strategic regulatory consulting closes the gap between your R&D file and a CE-marked product. Scope: technical documentation per MDR (EU) 2017/745 / IVDR (EU) 2017/746, clinical evaluation per MDCG 2020-13, ISO 14971 risk management, biocompatibility planning per EN ISO 10993, and post-market surveillance. The earlier you engage us, the fewer notified-body deficiencies you fight at submission — most issues we see were inherited from intended-purpose definitions made before regulatory was at the table.

Our regulatory consulting services include

End-to-end coverage from CE conformity through clinical evaluation to post-market surveillance.

CE conformity support

Support during CE conformity assessment procedures according to MDR (EU) 2017/745 and IVDR (EU) 2017/746.

Technical documentation

Preparation of complete technical documentation in line with regulatory requirements.

Risk management file

Preparation of product risk management file according to EN ISO 14971.

Clinical evaluation

Preparation of clinical evaluation for medical devices.

IVD performance evaluation

Regulatory support on performance evaluation for in vitro diagnostics.

Post-market surveillance

Post-market surveillance (PMS) planning and reporting throughout the device lifecycle.

SSCP summary

Summary of safety and clinical performance (SSCP) for higher-risk medical devices.

Gap analysis

Review and gap analysis for technical documentation to identify compliance gaps early.

Biocompatibility

Planning and reporting on biocompatibility activities according to EN ISO 10993-1 ff.

Industries we serve

Regulatory expertise across healthcare

Medical device manufacturing quality inspection

Medical Devices

Class I to Class III medical devices — CE conformity assessment, technical documentation, vigilance and post-market surveillance across the European Union.

In vitro diagnostics laboratory

In Vitro Diagnostics

Classification and compliance pathways for IVD manufacturers.

Pharmaceutical and biotech research

Pharmaceutical & Biotech

Regulatory strategy and quality management for pharma and biotech.

Common questions

Your questions about regulatory strategy

Strategy from device classification, intended use definition and clinical evaluation planning through MDR / IVDR conformity assessment, notified body selection, technical documentation, and submission preparation. We help you anticipate regulatory hurdles before they delay launch.

The earlier the better — ideally during early R&D when classification, intended purpose and clinical strategy are still being defined. Late-stage engagement is also possible, typically focused on rescuing dossiers or closing notified body deficiencies.

No. MT Promedt is an independent consultancy with no notified body affiliation — our advice is neutral. We work alongside all major notified bodies across the EU.

Yes. Our team supports both medical devices under MDR (EU) 2017/745 and in-vitro diagnostics under IVDR (EU) 2017/746, across all device classes.

Yes. We help prepare pre-submission packages, simulate audits, and accompany clients in NB consultations and audit days.

Once we’ve had a brief intro call and reviewed your device class and intended markets, we can return a fixed-scope or retainer-based proposal within a few business days.

Clients Feedback

What our clients say about us.

Example: Dr. E. Lindner

We were stuck on the classification of a combination product. After one workshop with the regulatory team, we had a clear rationale ready for our notified body — and it was accepted on the first review.

★★★★★
★★★★★
Example: M. Werner

Our clinical evaluation was failing scrutiny. The team rebuilt the literature search strategy, structured the safety and performance arguments per MDCG 2020-13, and got us through CE renewal without major findings.

★★★★★
★★★★★
Example: Dr. S. Reuter

What I value most: they push back when something is risky. On our last project they advised against shortcutting the risk file — three months later that decision saved us during an unannounced audit.

★★★★★
★★★★★
Additional resources

Download our Strategic Consulting brochure

Service brochure

Strategic Regulatory Consulting — English

EN444 KB

Strategic Regulatory Consulting — German

DE444 KB

Planning your CE mark or post-market strategy?

Get tailored regulatory consulting and a quote within 24 hours — from gap analysis to clinical evaluation, PMS and SSCP.

Request a strategy session